First goal is the evaluation of plasma and urinary FABP levels as useful indicators for diagnosis of intestinal ischemia. Second goal is to study whether combinations of proteins from the family of FABPs provide insight in the localization of…
ID
Source
Brief title
Condition
- Gastrointestinal vascular conditions
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Diagnosis of clinical relevant intestinal ischemia will be assessed by findings
during surgery or autopsy or experts.
We will find two groups: 1) patients without clinical relevant intestinal
ischemia and 2) patients with intestinal ischemia. A small group of patients
will remain in whom diagnosis is not clear. A group of experts will discuss
diagnosis.
At the end we will find a rest group with no clear diagnosis. We will report
them and calculate a worst-case scenario with these data.
Secondary outcome
None.
Background summary
Acute intestinal ischemia is potentially a lethal disease with high mortality
(60-80%!). This high mortality is caused by late diagnosis due to large
diversity of etiology of intestinal ischemia (arterial emboli, arterial
thrombosis, aorta dissection, etc) and low specificity and sensitivity of
current tests.
Therfore it is important to find useful diagnostic tools for patients who are
suspected for intestinal ischemia. Previous results show that Intestinal Fatty
Acid Binding Protein (I-FABP) is increased in patients with intestinal
ischemia. The clinical usefulness of FABPS in patients suspected for intestinal
ischemia is unknow. L-lactate and D-lactate are also potential predictors for
intestinal ischemia.
Study objective
First goal is the evaluation of plasma and urinary FABP levels as useful
indicators for diagnosis of intestinal ischemia.
Second goal is to study whether combinations of proteins from the family of
FABPs provide insight in the localization of intestinal ischemia.
Third goal is the assessment of L-lactate and D-lactate as useful markers for
diagnosis of intestinal ischemia.
Study design
All patients with suspicion for intestinal ischemia based on signs and symptoms
will be asked to participate in this prospective pilot-study. After informed
consent 5 ml blood and urine will be sampled as soon as possible and 4 hours
later.
Study burden and risks
Two times 5 ml blood will be sampled. At these time points we will ask the
patients to collect urine. This is no extra burden or risk for the patients.
P. Debyelaan 25
6229 HX, Maastricht
Nederland
P. Debyelaan 25
6229 HX, Maastricht
Nederland
Listed location countries
Age
Inclusion criteria
Patients admitted to AZM who are suspected for intestinal ischemia.
Exclusion criteria
None.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL15694.068.06 |